Login / Register The Most Trusted Name in Medical Education


Improve your knowledge in the field of surgery by taking one of Elsevier's complimentary continuing medical education courses.

910752 116 x 140

ESMO 2017: A Therapeutic Update on the Management of Patients with Advanced Hepatocellular Carcinoma

Format: Medical Meeting Reporter

This webcast on hepatocellular carcinoma (HCC) is based on a presentation by an expert, who provides an overview of the advances in the management of HCC and summarizes and discusses the latest data presented during the European Society for Medical Oncology (ESMO) Annual Meeting 2017, held on September 8-12 in Madrid, Spain. Results of clinical trials of targeted therapies that have been evaluated in first-line and second-line setting in advanced HCC and their possible effect on treatment guidelines will be examined. Additionally, the potential role of biomarkers as prognostic factors of response to targeted therapies, particularly in clinical practice, will also be discussed. The expert will also discuss the most promising new agents in advanced clinical trials in HCC and how they might impact the treatment landscape in HCC.

Take Course »


Credits: 1.0 AMA PRA Category 1 Credit™
910711 116 x 140

Real-world Experience With Neuromuscular Blockade Reversal

Format: Webcast

 Neuromuscular blocking agents (NMBAs) are used in many surgical procedures and have enabled new surgical advances. The expanded landscape of NMB reversal drugs allows for fast and complete neuromuscular blockade (NMB) reversal and the reduction of postoperative complications from residual block. In the United States, neostigmine/ glycopyrrolate and sugammadex are the primary agents for pharmacologic antagonism of NMBAs. While neostigmine and an anticholinergic have been available for decades, sugammadex has only recently become available. We present real-world cases in a variety of surgeries and clinical settings in which the use of NMB reversal agents played a significant role in the patients clinical outcome.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
SNO 116x141

New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint Inhibitors

Format: Webcast

The content for this activity is based on the satellite symposium, “New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint Inhibitors”, that was presented at the 21st Annual Meeting of the Society for Neuro-Oncology in Scottsdale, Arizona on November 17, 2016. Glioblastoma multiforme (GBM) remains one of the most feared of all malignancies due to its aggressive nature and correspondingly low survival rates. Recently, immunotherapies – particularly immune checkpoint inhibitors – have shown promise in treating patients with GBM in cases where conventional treatment options have failed. This archived symposium activity will provide participants with the opportunity to optimize the diagnosis and management of patients with GBM, including new data and remaining challenges resulting from recent clinical trials in the use of immune checkpoint inhibitors.

Take Course »

Credits: 1.50 AMA PRA Category 1 Credit(s)™